Inaugural Dealroom and NATO Innovation Fund Report Reveals Record-Breaking Investing in Startups in European Defence, Security, and Resilience Sector
12.2.2025 06:05:00 CET | Business Wire | Press release
The Defence, Security and Resilience sector reached $5.2 billion in 2024, an all-time high.The sector has outperformed the overall VC (Venture Capital) sector, marking a 30 percent increase over the past two years.Munich has emerged as the top VC hub in Europe for this segment in 2024.To help support the integration of the growing number of emerging technologies in this segment by governments and businesses, the NATO Innovation Fund is announcing the hiring of John Ridge as Chief Adoption Officer.
Dealroom.co and the NATO Innovation Fund - a €1 billion VC (Venture Capital) backed by 24 NATO countries – published today their inaugural report on the state of Defence, Security and Resilience in Europe, revealing a record-breaking year for investing in this segment. This highlights the critical role that the sector is playing in maintaining Europe’s technological edge and sovereignty amidst a broader market downturn.
Key findings from the report reveal:
- VC funding in the DSR (defence, security and resilience) sector is at an all-time high, reaching $5.2 billion in 2024. Overall, investing is up nearly 5x in the last six years. With companies in early and breakout stages driving this growth, a strong pipeline to scaling is expected in the coming years.
- DSR investing has increased by 30 percent over the past two years - the strongest growth among all VC deep tech segments. The segment has significantly outperformed the overall VC market, which witnessed a 45 percent decline in the same period of time.
- Defence startups have been leading in the segment’s growth. Companies developing technologies for Awareness, Understanding, and Decision Making – this includes technologies that help track risks and threats to enable faster and better decisions - have seen VC funding soar to a record $1 billion in 2024, up 4x since 2020 and nearly 2x since last year.
“Appetite for defence, security and resilience startup investment is unrecognisable in Europe from just a few years ago,” said Yoram Wijngaarde, Founder and CEO of Dealroom. “While overall VC funding contracted by 45 percent in the past two years, defence and security tech investment has grown by 30 percent to reach $5.2 billion last year. It follows an ongoing trend of putting capital and innovation to work on Europe's core strategic needs, via deep technologies. Despite recent growth, defence, security and resilience tech remains a relatively nascent sector, but the data shows an active pipeline of early-stage companies looking to change that.”
“Europe has the talent and resources to become a global leader in technologies for Defence, Security and Resilience,” said Kelly Chen, Partner at the NATO Innovation Fund. “We're excited to see this sector drive the momentum in Deep Tech this year and are committed to investing in technologies that can secure the region's future.”
Germany and the UK are emerging as regional leaders
- Munich emerged as Europe's top hub for DSR investment, followed by Oxford in the UK and Paris in France.
- The UK has attracted the most VC funding in DSR since 2019. However, Germany claimed the top spot in 2024, followed by the UK and France.
- Since 2019, Switzerland and the Netherlands have invested 7 percent of their total national VC funding in DSR companies. That marks the largest share of national funding invested in this segment.
- The UK boasts five of the top ten DSR hubs (Oxford, London, Cambridge, Bristol, and Reading), while Germany follows with two (Munich, Berlin).
“The Munich metropolitan region is becoming a hub for next-generation defence companies, offering industrial and testing facilities, top talent, a regional industrial supply chain, and connections to German defence customers and traditional primes,” said Marc Wietfeld, Co-Founder & CEO, ARX. “With ARX, we aim to bridge the gap between emerging players, new defence primes, and established contractors.”
Laying the foundation for technological adoption in Europe
The report’s findings indicate that Europe's emerging tech landscape is undergoing a significant transformation in the defence, security and resilience space, driven by geopolitical developments and a growing demand for emerging technologies that can secure the region’s future. In a recently released paper, the NATO Innovation Fund called for the creation of adoption pathways for the integration of emerging technologies in the defence and security infrastructure of European ministries of defence.
To help support with the creation of these pathways, as well as in order to connect large European businesses with startup founders who have developed deep tech solutions that can help the region maintain its technological edge for generations to come, the NATO Innovation Fund is announcing today the hiring of John Ridge as Chief Adoption Officer.
John joins the NATO Innovation Fund after spending nearly three decades in the UK’s Armed Forces and Civil Service. He is also a Commissioner on the Atlantic Council’s current Commission on Software-Defined Warfare.
“I am extremely proud to be joining the NATO Innovation Fund to help get the cutting-edge capabilities of our portfolio companies into the hands of users across the Alliance,” said John Ridge, Chief Adoption Officer, NATO Innovation Fund. “I look forward to working hand-in-hand with NATO, national governments and defence industry leaders to help the technologies that we are backing make a difference to the Alliance's ability to deter further aggression by our adversaries.”
About the NATO Innovation Fund:
The NATO Innovation Fund is a €1 billion venture capital fund, backed by 24 NATO Allies, that invests in deep tech to address challenges in defence, security, and resilience. The fund invests independently, with 24 nations supporting its portfolio’s success and helping provide deep tech entrepreneurs with access to both commercial and government markets.
Participating NATO Allies are: Belgium; Bulgaria; Czechia; Denmark; Estonia; Finland; Germany; Greece; Hungary; Iceland; Italy; Latvia; Lithuania; Luxembourg; Netherlands; Norway; Poland; Portugal; Romania; Slovakia; Spain; Sweden; Türkiye; United Kingdom.
About Dealroom.co:
Dealroom.co is a global intelligence platform for discovering and tracking the most promising companies, technologies and ecosystems. Clients include many of the world’s foremost organizations such as Sequoia, Accel, Index Ventures, NATO Innovation Fund, Nato Diana, ESA, McKinsey, BCG, Deloitte, Google, AWS, Microsoft, Stripe.
Dealroom partners closely with local tech ecosystem development agencies and enablers, to create a comprehensive multi-dimensional blueprint of the tech ecosystem, including capital, talent, innovation, entrepreneurship and overall economic dynamism.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250211886043/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom